Summit, a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infections, has appointed Dr David Roblin as Chief Medical Officer.
A qualified medical doctor, Roblin has extensive experience from an 18-year career in the industry during which he has been involved in the successful development of a number of important medicines in a range of therapy areas, including infectious and metabolic diseases.
He has held a number of senior leadership roles at Pfizer and Bayer where he was involved in research, development and commercialisation. At Pfizer, he was Head of Research, Site Director and CMO for Europe R&D. At Bayer, he was Head of Therapy Area for Anti-infectives where he was involved in the successful development of a number of antibiotics, including Avelox and Cipro.
Roblin will divide his time between Summit and Creabilis where he is also CMO. He is currently a Director of Destiny Pharma and Bio-Industry Advisor to the National Office of Research Infrastructure in the UK’s Department of Health.
